Dental Pulp Stem Cells Ameliorate Elastase-Induced Pulmonary Emphysema by Regulating Inflammation and Oxidative Stress
DOI: https://doi.org/10.2147/JIR.S402794
IF: 4.5
2023-04-09
Journal of Inflammation Research
Abstract:Xiaoli Gao, Zhiqiang Liu, Zuomin Wang Department of Stomatology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, People's Republic of China Correspondence: Zuomin Wang; Zhiqiang Liu, Department of Stomatology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongti South Road, Chaoyang District, Beijing, 100020, People's Republic of China, Tel +86 10 85231492, Email ; Background: Dental pulp stem cells (DPSCs) are considered excellent candidates for stem cell-based tissue regeneration. In this study, we aimed to evaluate the therapeutic effect of DPSCs in a mouse chronic obstructive pulmonary disease (COPD) model and to explore whether DPSCs reduce lung inflammation and oxidative stress by regulating the nuclear factor erythroid‐2 related factor‐2 (Nrf2) signaling pathway. Methods: DPSCs were isolated from dental pulp tissue by the tissue block method. Emphysema of C57BL/6 mice was induced by endotracheal administration of porcine pancreatic elastase (PPE). Then, the DPSCs were injected into the lungs through the trachea, and after 3 weeks of stem cell treatment, various efficacy tests were performed. The AniRes2005 animal lung function analytic system was used to detect lung function. Hematoxylin-eosin staining (H&E) and Victoria blue staining was used to assess emphysema severity. The animal tissues were detected by Western blot, RT‒qPCR, ELISA and oxidative stress related detection. Results: In experimental COPD models, DPSCs transplantation improved lung function, body weight, and emphysema-like changes better than bone marrow mesenchyml stem cells (BM-MSCs). Compared with the COPD group, the levels of IL-1β, TNF-α and IL-6 in lung tissue and bronchoalveolar lavage fluid (BALF) were decreased after transplantation of DPSCs. DPSCs may be associated with lower malondialdehyde (MDA) levels, and higher catalase (CAT) and glutathione (GSH) levels. Western blot results showed that the expression of Nrf2 and its downstream factors increased after transplantation of DPSCs. Conclusion: The current study showed that DPSCs had good performance in the treatment of a mouse COPD model and could be a promising option for stem cell therapy. DPSCs may play antioxidant and anti-inflammatory roles in COPD by activating the Nrf2 signaling pathway. Keywords: chronic obstructive pulmonary disease, dental pulp stem cells, Nrf2, inflammation, oxidative stress Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease, and it covers a diverse group of diseases with common functional features, such as chronic bronchitis, chronic respiratory failure, and emphysema. 1,2 Affecting nearly 400 million people, the World Health Organization predicts that COPD will be the third leading cause of death worldwide by 2030. Although progress has been made in treating symptoms and preventing acute exacerbations, little progress has been made in improving disease progression or affecting mortality. 3 COPD is a heterogeneous disease associated with irreversible airway obstruction, destruction of alveoli, and chronic inflammation. 4 In recent years, a hypothesis about the pathogenesis of chronic obstructive pulmonary disease is that the increase in reactive oxygen species (ROS) (directly caused by smoking and indirectly caused by the increase in reactive oxygen species released by inflammatory cells) may not be fully balanced by the lung antioxidant system, leading to oxidative stress. 5,6 Excessive oxidants may lead to increased expression of pro-inflammatory genes and protein release, inactivation of antiproteases, and oxidative tissue damage in COPD. 7 Therefore, treatments with antioxidant and anti-inflammatory properties may be beneficial in preventing or slowing the progression of COPD. Over the past few years, there has been a growing interest in the use of antioxidants as drug treatments for airway diseases. 8 Mesenchymal stromal cells (MSCs) are cells of nonhematopoietic origin that have the ability to differentiate into multiple lineages of mesenchyme. 9 Due to its potent and broad immunomodulatory activities, bacterial clearance, tissue regeneration and proangiogenic and antifibrotic properties, it offers a novel and promising therapeutic option, and its therapeutic effect has been confirmed in various types of lung disease, including chronic obstructive pulmonary disease. 10 While all MSCs have similar general properties, different sources of MSCs have an impact on growth factors, cytokines, extracellular vesicles and secreted bioactive factors in regenerative environments, thus affecting clinical outcomes. 11 Bone marrow is the traditional way of harvesting mesenchymal stem cells; however, -Abstract Truncated-
immunology